We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Interferon-Activated Gene Stabilizes Proteins Linked to Breast Cancer Spread

By LabMedica International staff writers
Posted on 26 Jan 2012
The product of a gene activated by interferon blocks the breakdown of proteins that lead to cellular invasiveness, which may cause cancer cells to metastasize and spread beyond the site of the original tumor.

Interferon-stimulated gene 15 (ISG15) is an ubiquitin-like protein that becomes conjugated to many cellular proteins upon activation by interferon-alpha. More...
The pathway incorporating ISG15 activity is highly elevated in breast cancer, but how the ISG15 pathway contributes to breast tumorigenesis had not been studied to any great extent.

In the current study, using the gene disruption approach (gene knock-down), investigators at the Louisiana State University School of Medicine (New Orleans, USA) demonstrated that both ISG15 and UbcH8 (ISG15-specific conjugating enzyme) disrupted F-actin architecture and formation of focal adhesions in ZR-75-1 breast cancer cells. In addition, ISG15 and UbcH8 promoted breast cancer-cell migration. They also demonstrated that ISG15 inhibited ubiquitin/26S proteasome-mediated turnover of proteins implicated in tumor cell motility, invasion, and metastasis.

The results, which were published in the January 2012 issue of the journal Experimental Biology and Medicine, suggest that the aberrant activation of the ISG15 pathway confers a motile phenotype to breast cancer cells by disrupting cell architecture and stabilizing proteins involved in cell motility, invasion, and metastasis.

First author Dr. Shyamal Desai, assistant professor of biochemistry and molecular biology at the Louisiana State University School of Medicine, said, “Using ISG15 and UbcH8 gene knocked-down approach, our recent published and unpublished results explicitly demonstrated that the ISG15 pathway inhibits the ubiquitin-mediated proteasome-dependent protein degradation in breast cancer cells. We were the first to recognize this antagonizing effect of ISG15 in cancer cells.”

“Disruption of cellular architecture is a hallmark of cancer,” said Dr. Desai. “The ISG15 pathway is also elevated in a variety of tumors. Our results therefore reveal that the ISG15 pathway, which is aberrantly elevated in tumors could disrupt cell architecture and contribute to breast cancer cell motility. Because the cellular architecture is conserved and the ISG15 pathway is constitutively activated in tumor cells of different lineages, our observations in breast cancer must hold true for many other tumors.”

Related Links:

Louisiana State University School of Medicine




New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Biochemical Analyzer
iBC 900
New
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A simple blood sample that allows DNA methylation could identify epigenetic biomarkers (Photo courtesy of 123RF)

Simple Blood Sample Could Identify Epigenetic Biomarkers to Predict CVD Risk in Type 2 Diabetes

People with type 2 diabetes face up to four times higher risk of cardiovascular events such as heart attacks, strokes, and angina compared to individuals without the condition. Yet, current tools used... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The new technology could predict who will benefit from immunotherapy (Photo courtesy of Max Delbrück Center)

New Technology Deciphers Immune Cell Communication to Predict Immunotherapy Response

A healthy immune system depends on complex communication between specialized cell types that detect, alert, and eliminate harmful threats. When these immune signaling pathways break down, the result can... Read more

Microbiology

view channel
Image: MycoMEIA Aspergillus Assay is the first FDA-cleared urine-based test for invasive aspergillosis (Photo courtesy of Pearl Diagnostics)

Urine-Based Assay Diagnoses Common Lung Infection in Immunocompromised People

Invasive Aspergillosis (IA), a life-threatening fungal infection, poses a serious threat to immunocompromised individuals, especially those with hematologic malignancies, transplants, or severe lung diseases.... Read more

Industry

view channel
Image: The acquisition of Exosome Diagnostics adds the ExoDx Prostate test to Mdxhealth’s portfolio (Photo courtesy of Bio-Techne)

Bio-Techne Divests Exosome Diagnostics to Reposition Product Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has entered into an agreement with Mdxhealth SA (Irvine, CA, USA), which will acquire its Exosome Diagnostics Inc. (Waltham, MA, US) business, including the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.